<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439203</url>
  </required_header>
  <id_info>
    <org_study_id>JM-010CS01</org_study_id>
    <nct_id>NCT02439203</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia</brief_title>
  <acronym>LID</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Contera Pharma ApS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of a randomized, double-blind, placebo-controlled, 2-way crossover study is to&#xD;
      evaluate the efficacy, safety/tolerability and pharmacokinetics of JM-010 for the treatment&#xD;
      of subjects with Parkinson's Disease (PD) with levodopa-induced dyskinesia (LID).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator-rated change in dyskinesia severity as assessed by the Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>7 Days</time_frame>
    <description>Investigator-rated change in dyskinesia severity as assessed by the AIMS after levodopa challenge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-rated Parkinsonian disability using Unified Parkinson's Disease Rating Scale (UPDRS) Part III</measure>
    <time_frame>7 Days</time_frame>
    <description>Investigator-rated Parkinsonian disability using UPDRS Part III after levodopa challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-rated change in PD effects as assessed through daily Dyskinesia Questionnaires</measure>
    <time_frame>Daily</time_frame>
    <description>Subject-rated change in PD effects as assessed through daily dyskinesia questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-rated change in dyskinesia severity as assessed by the Clinical Global Impression (CGI) scale</measure>
    <time_frame>7 Days</time_frame>
    <description>Subject-rated change in dyskinesia severity as assessed by the CGI scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as measured by assessment of abnormalities in physical examinations, safety laboratory examinations, 12-lead electrocardiogram (ECG) and vital signs; collection of adverse events (AEs)</measure>
    <time_frame>28 Days</time_frame>
    <description>Assessment of abnormalities in physical examinations, safety laboratory examinations, 12-lead electrocardiogram (ECG) and vital signs; collection of adverse events (AEs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Levodopa Induced Dyskinesia (LID)</condition>
  <arm_group>
    <arm_group_label>JM-010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JM-010</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JM-010</intervention_name>
    <arm_group_label>JM-010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Subject with a diagnosis of moderate to severe idiopathic PD with showing&#xD;
             responsiveness to levodopa.&#xD;
&#xD;
          -  All anti-Parkinsonian medications and levodopa must be stable for at least 1 week&#xD;
             prior to the start of the run-in period.&#xD;
&#xD;
          -  Subject with stable predictable peak-effect LID of at least 2 hours of the awake day&#xD;
             and with at least moderately disabling.&#xD;
&#xD;
          -  Amantadine and/or monoamine oxidase (MAO) inhibitor must be stopped at least 2 weeks&#xD;
             prior to the start of Treatment Period 1(TP 1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis is unclear or a suspicion of other Parkinsonian syndromes exists, such as&#xD;
             secondary Parkinsonism, Parkinson-plus syndromes or other neurological degenerative&#xD;
             diseases.&#xD;
&#xD;
          -  History of any other brain surgery or surgery for the treatment of PD.&#xD;
&#xD;
          -  Current primary psychiatric diagnosis of acute psychotic disorder or other primary&#xD;
             psychiatric diagnoses.&#xD;
&#xD;
          -  A history of psychosis and/or treatment with antipsychotics within 3 months prior to&#xD;
             the start of Treatment Period 1(TP1).&#xD;
&#xD;
          -  A history of, or current, seizure disorders and subjects requiring treatment with&#xD;
             anti-convulsants.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory data at screening.&#xD;
&#xD;
          -  Clinically relevant ischemic heart symptoms or history of myocardial infarction,&#xD;
             coronary artery bypass surgery or percutaneous transluminal coronary angioplasty,&#xD;
             within the previous 12 months prior to the start of TP1.&#xD;
&#xD;
          -  History of cerebrovascular accident or transient ischemic attack, coronary&#xD;
             vasospasm/Prinzmetal's angina.&#xD;
&#xD;
          -  History of serotonin syndrome.&#xD;
&#xD;
          -  Breast feeding or pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Levodopa Induced Dyskinesia (LID)</keyword>
  <keyword>Dyskinesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

